Patients with cystic fibrosis (CF) are being considered in increasing numbers as candidates for lung transplantation, despite earlier concerns that their nutritional status and the infective nature of their lung disease would contribute to increased morbidity and mortality. We undertook a retrospective analysis of patients with CF referred for consideration of lung transplant to identify factors that helped to select suitable transplant candidates and to identify characteristics that predicted death while on the waiting list. Analysis of 95 referred patients with CF demonstrated a high rate of suitability (78%) by our criteria. The mean weight of listed patients with CF was 77% predicted, and the mean FEV1 was 20% predicted. Sixteen percent of listed patients
In the last decade, lung transplantation has emerged as a reasonable therapy for patients with endstage lung disease.' 2 Patients with cystic fibrosis (CF) were initially considered for heart-lung transplant. 3 As experience has accumulated with double lung transplant, this has emerged as the preferred procedure of for patients with CF, particularly in North America. [4] [5] [6] [7] The growing popularity of lung transplantation and the relative scarcity of suitable lung donors has resulted in a progressively longer wait for potential lung transplant recipients.
To aid in selection of recipients with CF for lung transplantation, Kerem and others8 from the University of Toronto Cystic Fibrosis Center analyzed death in their center. Using regression analysis, these authors identified the probability of death within 2 years from a variety of parameters of lung disease in patients with CF.8 These data may be useful to determine timing of lung transplant referral.
We performed a retrospective analysis of all patients with CF who were referred to our lung with CF died awaiting transplant. The FEV1 of these patients was significantly lower than that of patients who survived to transplant. This study implies that patients with CF 
RESULTS
Between January 1990 and July 1993, 95 patients with CF have been seen at University of North Carolina Hospitals for consideration of lung transplantation. The age distribution of patients is depicted in Figure 1 . The mean age of all referrals was 23.9 years (range, 7 to 45 years). The group consisted of 51 female and 44 male patients. The outcome of referral and subsequent evaluation for selected patients is depicted in Figure 2 . Seventy-four of the 95 patients were considered acceptable for transplantation. Of these, seven refused transplantation at our institution. Three were listed or underwent transplantation at other institutions, while four simply chose not to undergo transplantation. Sixty-seven patients were listed for transplantation; to date, 31 patients have undergone double lung transplant using the bilateral sequential technique.10 Twenty-five patients remained listed as of July 1993, and 11 patients have died on the waiting list.
Eleven of the 95 referrals were considered to be "too well" for transplantation at the time of referral and are being followed up. Ten patients had identified contraindications; these are listed in Table 2 . Inability to wean from high-dose systemic steroid (>20 mg/d) therapy is considered a contraindication in our program. A bone density of less than 4 SDs below the mean is a relative contraindication and has been used, on occasion, to exclude patients from consideration for transplantation. Poor A 6-min walk performed at evaluation averaged 379.5 m for 67 patients who were considered acceptable for transplantation. Most patients who were deemed too well did not undergo the 6-min walk that was performed as part of an in-hospital evaluation after outpatient screening. Accordingly, data on the 6-min walk are available for only 3 of the patients who were deemed too well; the mean distance was 498.3 m. This difference did not reach statistical significance.
Exclusion of patients with identified contraindication or those deemed too well allowed for analysis of differences among patients listed with respect to survival on the list to transplant. Eleven of 67 listed patients died prior to transplantation. The clinical variables for these two subgroups of listed patients are summarized in Table 4 . No significant differences were found between the groups with respect to age, sex, weight, right ventricular ejection fraction, or Oxygen utilization was found more frequently among patients who were acceptable for transplant. Indeed, all patients accepted for transplant used oxygen at some point (12 with exercise and 61 at rest), while 9 of 11 patients deemed too well for transplant did not use oxygen at all. The other two used oxygen only with exercise. All patients with an identified contraindication were oxygen dependent at rest. Not surprisingly, all patients who died waiting were oxygen dependent at rest, as well.
Arterial blood gas determinations were not always performed during evaluation; they were recorded for two thirds of listed patients during their in-hospital evaluation. The Pco2 was marginally higher at evaluation among patients who subsequently died waiting (mean Pco2, 54) compared with patients who had undergone transplantation (46) or listed patients (50), but this difference did not reach significance by ANOVA.
The outcome of patients who had undergone transplantation is reported elsewhere.1" All patients with transplants have survived to hospital discharge; actuarial 1-year survival is 85% for patients with transplants with CF end-stage lung disease. to be acceptable candidates for lung transplantation.
It is not surprising that the mean FEV1 of our candidates was in the range of 20% predicted. This degree of pulmonary involvement is indicative of a poor outcome. In fact, Kerem et a18 indicate that an FEV1 of less than 30% predicted is associated with a 40% actuarial chance of death within 2 years for male subjects; the actuarial chance of death in female subjects is even higher. Accordingly, percent predicted FEV1 has been used by our program as an indicator for patient selection. Other factors that influence our decision to accept patients for transplant include a history of reducing exercise tolerance in the face of increasing oxygen requirement and a history of increasing requirement for hospitalization to control infectious exacerbations of CF.
We currently have no experience with combined double lung/liver transplants, although we have listed one patient for this procedure. There is limited experience with heart-lung/liver transplant in patients with CF.13 In properly selected patients with an experienced lung and liver transplant team, this is likely a reasonable approach. Surprisingly, renal dysfunction was not seen frequently among referrals, despite the widespread use 
